Alexza files Staccato loxapine in the US
This article was originally published in Scrip
Executive Summary
Alexza Pharmaceuticals has filed an NDA with the US FDA for Staccato loxapine (AZ-004), an inhaler for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.